Skip to content

Evaluation of Therapeutic Adherence to Inciting Spirometry in Sickle Cell Patients

Evaluation de l'Observance thérapeutique à la spirométrie Incitative Chez Les Patients drépanocytaires

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04667325
Enrollment
15
Registered
2020-12-14
Start date
2021-01-01
Completion date
2021-02-01
Last updated
2021-02-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sickle Cell Disease

Keywords

acute chest syndrome, incentive spirometry, compliance

Brief summary

Sickle cell disease is one of the most common genetic diseases in the world. (1) It is characterized by the production of abnormal hemoglobin mainly responsible for vaso-occlusive clinical manifestations and chronic hemolysis with anemia. (2) It is therefore a chronic disease with major acute complications, such as acute chest syndrome. The treatment for this syndrome will be based on oxygenation, hydration and analgesia. At the physiotherapy level, we will have an action on the prevention and treatment of the syndrome by incentive spirometry. (3,4) In fact, it is currently the only physiotherapy treatment that has proven its effectiveness and is recommended for sickle cell patients. (3) As part of prevention, it is recommended to prescribe incentive spirometry during vaso-occlusive crisis. It has been shown to reduce the risk of atelectasis and significantly limit the risk of developing ACS. (5) In treatment, it makes it possible to regain normal chest amplification and therefore to allow ventilation of unventilated areas. (3.4) However, in order to increase therapeutic efficacy, patient compliance is essential. Adherence to treatment is a major problem in chronic diseases. Currently, it is estimated that 80% of patients with chronic conditions do not sufficiently follow their therapy, which limits the optimization of benefits. (6) This is the case in sickle cell patients, especially with hydroxyurea which is their disease-modifying treatment. Lack of adherence is the most common cause of primary failure of this treatment. During various treatments, we noticed the patients' lack of compliance with spirometry. Indeed, we explained to the patient how to do the incentive spirometry, so that he could practice it several times a day as recommended. When we returned the next day, or after a weekend, most of the time the patients had little or no observance. So I wanted to know if this concerns a majority of patients with sickle cell disease. Indeed, it appears important to assess compliance in these patients in order to improve the effectiveness of treatment and reduce the risk of ACS.

Interventions

None listed

Sponsors

Centre Hospitalier Intercommunal Creteil
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients with sickle cell disease, * Major * No opposition for participation in the protocol

Exclusion criteria

* Patients unable to answer the questionnaire due to linguistic or other problems * Patients under guardianship or curatorship

Design outcomes

Primary

MeasureTime frameDescription
To take stock of the observance of sickle cell patients with inciting spirometryThrough study completion, an everage of 10 minutesMeasuring compliance through the questionnaire

Secondary

MeasureTime frameDescription
To take stock of patients' knowledge of their pathology and incentive spirometryThrough study completion, an everage of 10 minutesAssessing knowledge about their pathology and treatment via the questionnaire
Measuring adherence to medical follow-upThrough study completion, an everage of 10 minutesMeasuring the number of consultations via the questionnaire
Assessing the impact of the disease on quality of lifeThrough study completion, an everage of 10 minutesMeasuring the patient's quality of life via the questionnaire

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026